Related Experiment Video
Updated: May 25, 2026
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
[Systemic therapy for advanced endometrial cancer]
Youssef Tazi1, Patricia Pautier, Catherine Lhommé
1Institut Gustave-Roussy, département de médecine, comité de gynécologie, Villejuif, France. youssef.tazi@igr.fr
Bulletin Du Cancer
|January 13, 2012
Summary
Advanced endometrial cancer has limited treatment options. Hormone therapy is suitable for slow-progressing, receptor-positive tumors, while chemotherapy offers higher response rates but significant toxicity. Targeted therapies show promise.
Area of Science:
- Gynecologic Oncology
- Medical Therapeutics
- Cancer Biology
Background:
- Endometrial cancer typically has a good prognosis if diagnosed early.
- Advanced or metastatic endometrial cancer presents a significant therapeutic challenge with limited effective treatment options.
Purpose of the Study:
- To review current and emerging therapeutic strategies for advanced endometrial cancer.
- To highlight the role of hormone therapy, chemotherapy, and targeted therapies.
Main Methods:
- Literature review of established and investigational treatments for advanced endometrial cancer.
- Analysis of treatment efficacy, toxicity profiles, and biological rationale.
Main Results:
- Hormone therapy is a preferred option for slowly progressing, hormone receptor-positive tumors due to its safety.
- Combination chemotherapy regimens (taxanes, anthracyclines, platinum compounds) demonstrate higher response rates but considerable toxicity.
- Targeted therapies, informed by tumor biology, are under investigation and show promising outcomes.
Conclusions:
- Treatment selection for advanced endometrial cancer depends on disease progression and tumor characteristics.
- While chemotherapy offers efficacy, its toxicity necessitates careful consideration.
- Targeted therapies represent a promising frontier for improving outcomes in advanced endometrial cancer.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...